VU590

CAS No. 313505-85-0

VU590( —— )

Catalog No. M33947 CAS No. 313505-85-0

VU590 is a potent and moderately selective inhibitor of extrarenal medullary potassium ROMK (Kir1.1) that also inhibits Kir7.1 and modulates uterine myometrial contractility and melanocortin signalling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 57 Get Quote
10MG 93 Get Quote
25MG 150 Get Quote
50MG 227 Get Quote
100MG 335 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VU590
  • Note
    Research use only, not for human use.
  • Brief Description
    VU590 is a potent and moderately selective inhibitor of extrarenal medullary potassium ROMK (Kir1.1) that also inhibits Kir7.1 and modulates uterine myometrial contractility and melanocortin signalling.
  • Description
    VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 is not a good probe of ROMK function in the kidney.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Potassium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    313505-85-0
  • Formula Weight
    488.53
  • Molecular Formula
    C24H32N4O7
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (102.35 mM; Ultrasonic (<60°C)
  • SMILES
    Cl.Cl.[O-][N+](=O)c1ccc(CN2CCOCCOCCN(Cc3ccc(cc3)[N+]([O-])=O)CCOCC2)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bhave G, et al. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol. 2011 Jan;79(1):42-50.?
molnova catalog
related products
  • Retigabine dihydroch...

    Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?

  • Tolazamide

    Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes.

  • Aprikalim

    Aprikalim (RP 52891) is an adenosine triphosphate potassium channel (KATP) opener that protects against nerve damage in a rabbit model of spinal cord ischemia.Aprikalim inhibits vasoconstriction and inhibits the elevation of [Ca2+]i during myocardial paralysis, and can be used to study cardiovascular disease.